Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Stannsoporfin - InfaCare Pharmaceuticals

Drug Profile

Stannsoporfin - InfaCare Pharmaceuticals

Alternative Names: Sn-mesoporphyrin; Stanate; tin-mesoporphyrin; Torcan

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rockefeller University
  • Developer InfaCare Pharmaceutical Corporation; National Hospital of Pediatrics
  • Class Antirheumatics; Heavy metals; Hepatoprotectants; Mesoporphyrins
  • Mechanism of Action Decyclizing heme oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hyperbilirubinaemia

Most Recent Events

  • 22 Aug 2018 Mallinckrodt receives complete response letter from the US FDA for stannsoporfin in Hyperbilirubinaemia (In neonates)
  • 24 Jun 2018 Biomarkers information updated
  • 03 May 2018 The US FDA's Gastrointestinal Drugs Advisory Committee and Paediatric Advisory Committee votes 21 to 3 that risk-benefit profile of stannsoporfin does not support approval for the treatment of Hyperbilirubinaemia (In neonates)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top